During the month August, minister Bruins threatened to ‘name and shame’ pharmaceutical companies when they lack transparency or substantiation regarding drug prices. Positive GVS advice for subgroup of MS-patients treated with Fampyra. CieBOM positive about olaparib as maintenance treatment after primary treatment of advanced epithelial ovarian carcinoma. No CHMP outcomes due to summer recess.
Minister Bruins wants to force pharmaceutical companies to provide more price transparency under pressure of public naming and shaming
Minister Bruins threatens to scandalize pharmaceutical companies if they offer no price substantiation, he wrote in de Volkskrant. If pharmaceutical companies do not take their social responsibility, the minister believes that publicity pressure should induce them to do so.
In an open letter in the Volkskrant, minister Bruins directly addresses pharmaceuticals on their social responsibility. “Extreme prices, profiteering and a total lack of transparency do not fit their important social position,” said the minister. He will soon be talking to an – unnamed – pharmaceutical company that has raised the price of a drug to around €150,000. Bruins will be asking the company to go public if they have a plausible explanation for their price increase. If not, he will consider subsequent steps such as negative publicity. A good story is therefore also in the interest of the pharmaceutical company, Bruins argues.
Dutch Pharmaceutical Market
Axon publishes a monthly article in English that presents an overview of the Dutch pharmaceutical market. On top of the regular monthly update this month’s issue presented a more comprehensive quarterly pharmaceutical market overview to put the numbers into context and provide more background on Dutch drug policy, market dynamics and other pharma related topics.
In July, the Dutch pharmaceutical market increased by 58 million euros to 6,297 million euros, MAT. Market growth was at 6%. The volume of the Dutch market in Days of Treatment increased slightly from 10,367 to 10,406 million, MAT. Growth of volume was 1,7%, MAT.
Click here (pdf) for the full overview of this month’s charts and tables.
No ACP (Advisory Committee Package) outcomes August due to summer recess
Positive GVS advice for reimbursement of fampridine (Fampyra) for a subgroup of patients with multiple sclerosis (MS)
Following a previously negative recommendation, the Healthcare Institute has now issued a positive recommendation to include fampridine (Fampyra, Biogen) in the GVS for a specific subgroup of people with MS. Extra conditions apply: patients must show an improvement of at least 20 percent in walking ability during the first period of treatment. The drug fampridine is used to improve walking in a proportion of adult patients with multiple sclerosis (MS) with severe walking difficulties.
CieBOM positive about olaparib as maintenance treatment after primary treatment of advanced epithelial ovarian carcinoma
The BOM Committee (CieBOM) has issued a preliminary positive recommendation for olaparib (Lynparza, AstraZeneca) as maintenance treatment after primary treatment, for women with advanced epithelial ovarian carcinoma (EOC), tuba carcinoma or primary peritoneal carcinoma, with a BRCA mutation and a response on the primary treatment. The study resulted in an estimated 3-year progression-free survival of 60 percent (olaparib) versus 27 percent (placebo). The data are still too premature for analysis of overall survival. As soon as definitive data on the overall survival become known, these will also be assessed by the CieBOM. In the Netherlands, an annual EOC is set for 1,100 women. EOC usually gives symptoms in a late stage of the disease, which means that nearly 70 percent of patients already have the disease at an advanced stage when they are diagnosed (stage IIB and higher).
No CHMP outcomes August due to summer recess
Bron: Axon Connect, Committee for Medicinal Products for Human Use (CHMP), Farminform, Zorginstituut Nederland (ZiNL)